Self Selection Studies News Today

Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)

Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDANEW YORK, NY / ACCESSWIRE / May 21, 2024 / Petros

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading ...

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review ...

FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development pr...

Petros Pharmaceuticals Demonstrates Positive Results Following Successful ...

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) ...

Petros Pharmaceuticals Successfully Completes Important Study in Effort ...

The regulations, which the FDA is currently finalizing, introduced Additional Conditions for Nonprescription Use (ACNU) criteria that enable correct self-selection by consumers.

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) ...